Navigation Links
Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain

Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings announced that its national print advertising campaign for Cobroxin, the first clinically proven, over-the-counter treatment for moderate to severe (stage 2) chronic pain, is scheduled to begin in November and will run in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.

(Vocus) September 4, 2009 -- Cobroxin, which was developed by Nutra Pharma Corporation (OTCBB: NPHC), is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) chronic pain. In August, Nutra Pharma granted XenaCare Holdings the exclusive license for marketing and distributing Cobroxin throughout the United States.

XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it will begin its national print advertising campaign for Cobroxin in November. The campaign, which is budgeted at approximately $550,000, is scheduled to run through December and will appear in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self magazines.

“This advertising campaign represents the first of several national campaigns we plan to roll out as we introduce Cobroxin through national retailers in the coming months,” explained Frank Rizzo, President of XenaCare Holdings, Inc. “In addition to print advertising, we are also finalizing online marketing campaigns and television commercials,” he concluded.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
2. Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications
3. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
4. NutraCea Appoints New Chief Financial Officer
5. Synutra Announces Postponement of Proposed Offering
6. Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties
7. Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
8. Lixte Biotechnology Holdings Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
9. Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2009 Results
11. EFT BioTech Holdings, Inc.s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait
Post Your Comments:
Related Image:
Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
Breaking Biology Technology:
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):